A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
about
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVAbacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSubstituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentDetermination of abacavir in human plasma by high-performance liquid chromatography with ultraviolet detection and the analytical error function.Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTIChanging patterns in the selection of viral mutations among patients receiving nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse transcriptase.Safety analysis of ZiagenĀ® (abacavir sulfate) in postmarketing surveillance in JapanNovel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effectsAntiretroviral treatment of HIV infected adultsSwitching effective antiretroviral therapy: a review.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeTreatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review.Practical discussion on switching studies and how this relates to managing lipids.Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.Strategies for management and treatment of dyslipidemia in HIV/AIDS.Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.Simplification strategies to reduce antiretroviral drug exposure: progress and prospects.Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.Integrase inhibitors in the treatment of HIV-1 infection.Mechanism of HIV antiretroviral drugs progress toward drug resistance.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).Simplified therapy with zidovudine, lamivudine, and abacavir for very nonadherent, treatment-failing patients.Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
P2860
Q24202180-AB0A798F-2D1B-4756-BF50-1D5F2435D4C4Q24799351-AEBCBF63-CA12-4720-AC92-AC49BDDFB2B3Q24803596-D78A4510-24A5-4A73-B748-9C038B24CC4DQ33207117-FA94487D-9CF0-44A9-9A07-851FF178C202Q33803473-72FA05D0-09E9-45FF-A9F8-CF54EF6F93E7Q34414078-D0B245FC-8D72-4A12-9065-6598F091FDAEQ34503521-D0B305E7-EA73-4A42-80FD-B2936735B297Q34691351-4B624D2A-CC40-4C1C-9E9C-33C78F7F7058Q34693248-F3EAEE7A-0018-439C-AA88-5209CCB2B207Q34985833-CCA472DF-1BEC-4D34-8177-850BF72D961AQ35124959-EA1B00EB-CDF7-4C29-9CF8-864512D54AF5Q35147189-43A7AA71-543D-4114-900A-3C85654D5DD4Q35805765-1E7C03DF-6C66-4CD1-8C07-D3A829C765EFQ36292308-A226E57B-9AEA-4A14-A6CF-1E5E58C9D20DQ36322100-B6F8D662-9FD0-4699-8E6F-6DBECB529078Q36336563-333EDCC3-8891-4BEE-806C-E86FF3B733ECQ36632238-C48EA835-7F17-4061-9329-5137CD64BD68Q37277829-4FA8B1BA-B383-4154-AA53-DC701C344034Q37463958-9DE40553-9FE0-49FD-9E3A-8DC141B3D9CBQ37790212-4D57B44B-B578-42D3-9371-54A0F99FB7A5Q37961181-B270CE7F-6948-49BB-83EC-0586170C42C9Q38030981-DA47510C-70A8-4F0C-A56D-AA44DBA39DE8Q38959260-364D820D-3F2C-4082-865F-3F09E55BDD44Q38959269-A4E6CDB0-C97C-4C35-B300-E29E2F0001E3Q41619728-33084AC4-C1A1-4A69-8194-A5C70E9B3456Q42269396-C017E743-27E2-43F0-BC80-711A4B2AE7FBQ44408004-F238FCDE-E115-4AFC-A809-9CD9C3C277CBQ44657176-8AD2D119-3FF1-4438-BFC0-4E0C463C961DQ44806177-491D286C-8B2C-4980-852C-70277A598A04Q44873292-4FF7D65E-1461-4381-A0A3-3FFD4F65BA42Q45419995-B7CAA5A0-9415-4B5C-AFEB-8A39C34BEE64Q46474207-2D8D4C98-959F-4FC3-810B-021221E33AE7Q46899234-F80E82CC-AC34-4FFD-9140-5A5B0EE0EF3DQ46935128-ABB49494-7F6D-4BF5-98FD-737BF1B37CACQ53851252-141683F7-3724-4159-B05A-B5769AF67C14
P2860
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.
description
2002 nĆ® lÅ«n-bĆ»n
@nan
2002 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō±ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2002 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ”ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2002幓ć®č«ę
@ja
2002幓č«ę
@yue
2002幓č«ę
@zh-hant
2002幓č«ę
@zh-hk
2002幓č«ę
@zh-mo
2002幓č«ę
@zh-tw
2002幓č®ŗę
@wuu
name
A randomized trial of simplifi ...... unodeficiency virus infection.
@ast
A randomized trial of simplifi ...... unodeficiency virus infection.
@en
A randomized trial of simplifi ...... unodeficiency virus infection.
@nl
type
label
A randomized trial of simplifi ...... unodeficiency virus infection.
@ast
A randomized trial of simplifi ...... unodeficiency virus infection.
@en
A randomized trial of simplifi ...... unodeficiency virus infection.
@nl
prefLabel
A randomized trial of simplifi ...... unodeficiency virus infection.
@ast
A randomized trial of simplifi ...... unodeficiency virus infection.
@en
A randomized trial of simplifi ...... unodeficiency virus infection.
@nl
P2093
P50
P356
P1476
A randomized trial of simplifi ...... unodeficiency virus infection.
@en
P2093
Bruno Ledergerber
Colin Howe
Jean-Philippe Chave
Leslie R Bisset
Luc Perrin
Marek Fischer
Milos Opravil
Pietro Vernazza
Rainer Weber
P304
P356
10.1086/340312
P407
P50
P577
2002-04-01T00:00:00Z